Datar Cancer Genetics (DCG), a global leader in non-invasive cancer diagnostics, announces Dr. Massimo Cristofanilli as Strategic Advisor, reinforcing its commitment to advancing early cancer detection and precision treatment.
Feb. 2025
Read MoreDatar Cancer Genetics (DCG) has launched Exacta AI, a next generation multi-analyte AI-driven platform providing optimised treatment options for cancer patients who have exhausted the standard options.
Feb. 2025
Read MoreDatar Cancer Genetics (DCG) has launched a revolutionary video-reporting service for in-vitro chemosensitivity testing, powered by AI-driven technology. This innovation provides oncologists with real-time visual evidence of chemotherapy drugs' effectiveness on a patient's tumor cells, derived from tissue biopsies or blood.
Jan. 2025
Read MoreThe Target-MRD blood test uses a combination of tumour-informed and tumour-agnostic molecular features for personalised, accurate and more effective monitoring of molecular residual disease.
Jan. 2025
Read MoreBRAIN TUMOUR RESEARCH
Dec. 2023
Read MoreCromwell Hospital, a world-leading private hospital in London, is working with Datar Cancer Genetics as a trusted second opinion partner.
Oct. 17, 2023
Read MoreLord Ian Botham talks not just about racism but also the value of early cancer detection as he recently took the multi-cancer detection solution Trucheck™ Intelli.
Aug. 10, 2023
Read MoreDatar Cancer Genetics now has three Breakthrough Designations granted by the USFDA, including liquid biopsies for breast and prostate cancer detection.
Jan. 2, 2023
Read MoreThe Trucheck™ Intelli blood test can identify 70 types of cancer, with the company hoping it can be rolled out across the NHS
Oct. 28, 2022
Read More'Game-changer' blood test detects breast cancer earlier than X-rays, study shows.
July 24, 2022
Read MoreLandmark Liquid Biopsy Study Shows Accurate Detection of Early-Stage Breast Cancer.
July 13, 2022
Read MoreDatar Cancer Genetics enters into partnership with The London Clinic to offer enhanced cancer testing services
April 11, 2022
Read MoreDatar's TriNetra-Prostate Blood Test Gets FDA Breakthrough Designation.
February 14, 2022
Read MoreGroundbreaking high-sensitivity cancer screening test arriving in SA ahead of World Cancer Day.
February 2, 2022
Read MoreVirtus Group announces partnership with Datar Cancer Genetics for personalised precision oncology solutions in Kuwait.
December 7, 2021
Read MoreUS FDA Grants Breakthrough Designation for Early-Stage Breast Cancer Detection Blood Test Developed by Datar Cancer Genetics.
November 19, 2021
Read MoreThe Top 25 Women Leaders in Biotechnology of 2021 (Swati Deshpande - Datar Cancer Genetics)
October 19, 2021
Read MoreUK - National Institute for Health and Care Excellence (NICE) issues MedTech Innovation Briefing on 'Trublood-Prostate' for Precision Non-Invasive Prostate Cancer Diagnosis Described by Experts as a 'Game Changer'.
July 13, 2021
Read More